GSK’s (LSE: GSK) share price is 9% down from its 15 May 12-month traded high of £18.19. This compounds the stock’s already extreme undervaluation against its competitors apparent to me beforehand.

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

London open The FTSE 100 is expected to open 10 points higher on Friday, having closed up 0.57% on Thursday at 8,240.97.

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

The drug is positioned as a follow-up product to GSK’s blockbuster Advair/Seretide, but the company is now facing generic competition against its older drug, plus new rivals from the likes of ...

Analyst Graham Parry from Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) and keeping the ...

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza ... regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry ...

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpointsVaccine candidate based on CureVac's p ...